While not life threatening, blindness and retinal disease are profoundly debilitating and greatly affect quality of life. Understandably, gene therapy has been subject to controversy given it’s potential effects on the rest of our cellular processes. However, a genetically diseased eye being an isolated organ quickly becomes a promising prospect for such therapies. Specifically, RPE antibodies are powerful diagnostic tools to test the viability of these clinical treatments.
